They are protein-based laboratory tests that can help predict the onset of acute kidney injury or monitor disease progression and treatment response in chronic kidney conditions. With rising incidences of diabetes, hypertension, and other lifestyle diseases leading to increased risk of kidney damage, the demand for renal biomarkers is growing substantially.
The global Renal Biomarkers Market is estimated to be valued at US$ 1700.59 Mn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing prevalence of renal diseases: One of the major factors driving the growth of the renal biomarkers market is the rising prevalence of chronic kidney diseases worldwide. According to statics, 1 in 10 adults across the globe are estimated to have chronic kidney disease. Early detection of kidney injury is critical to delay or prevent progression to end-stage renal disease. This is increasing the demand for sensitive and specific renal biomarkers for early diagnosis and progression monitoring of kidney conditions. Continuous development of novel and improved renal biomarkers by market players will further support the market growth in the coming years.
Segment Analysis
The Global renal biomarkers market size is segmented by product, indication, and end user. Based on product, the assays kits and reagents segment is expected to dominate the market over the forecast period. This is majorly due to the increasing urinary tests done to detect kidney disorders. These kits offer convenient solutions for detecting various kidney related diseases.
Key Takeaways
The global Renal Biomarkers Market is estimated to be valued at US$ 1700.59 Mn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024-2031.
Regional analysis shows that North America is currently the largest as well as the fastest growing market for renal biomarkers. The rising prevalence of chronic kidney disease along with growing elderly population prone to kidney disorders are major factors driving high demand. According to the National Kidney Foundation, over 30 million Americans currently have chronic kidney disease.
Key players analysis shows that major players operating in the renal biomarkers market include Thermo Fisher Scientific Inc., Abbott, F. Hoffmann-La Roche AG, Beckman Coulter Inc., (Danaher Corporation), and Siemens Healthcare Private Limited. Thermo Fisher Scientific Inc. offers a wide portfolio of renal biomarkers instruments, assays and consumables for clinical research applications.
Get More Insights On This Topic: https://www.newsstatix.com/renal-biomarkers-market-size-share-analysis-2023-2030/
Comments
0 comment